Member Info for smudge99

I believe the bod basically confirmed the business will be unaffected by the pending downturn and any share price recovery will be when the money re-enters the markets. With the amount of products and potential I'm hoping the bod are correct and can provide greater clarity in the next update. Needs something that most aim companies can't offer and that's an accurate forecast.

I'm not too surprised with the outlook as there were a few signs at the last update that things weren't going to plan eg lab shut down, nell employees/cfo leaving after a short duration. Be interesting to see how this is narrated in the presentation tomorrow. I might be reading between the lines but it does look boots and loyds are supporting this company as they went for mhc for the lft and superdrug presumably went elsewhere. Whether the wellness dna are the right ones for retail I don't know but I'd hope the next set will be. Hopefully the presentation will shed some light on these and the ip behind it. Looks like the plot continues on this one.

Thought the recent ekf presentation was interesting when asked about the nipt market size and they mentioned that lyn yourgene has probably covered that. Looks like no one knows! Interesting that they mentioned the other big players as perkin elmer (non ngs) and natera (ngs). I can't find any figures from these companies as to the nipt tests processed just total test numbers. Is pe involved with ygen? Might need to update their test to ngs maybe? Seems like their current turnaround time is 7 days rather than the 48hrs ekf is quoting.

Here's a snapshot of August website hits. Not sure how accurate it is though but it has dipped
https://www.similarweb.com/website/myhealthchecked.com/#overview
Wondered if there was anything to read into the glucose test not being on amazon but available on their website. The flowflex lft seem to still be selling but not sure how significant the quantities are.

I appreciate it's a small company and expectations may have grown too big too soon but there are a couple of things that I can't work out. Most of the h1 revenue was down to the lft sales, I'm guessing the general ones rather than travel. No rns for either the lloyds or boots general lft distribution until eluded to in the June update. No mention of the h2 app to supplement the wellness tests which leads into the road map. Anybody reading the last two road maps might question how much they adhered to it. Also the acquisitions, I don't believe we have products from the genome store but got the lab expertise and the covid pcr related work. The lab has now been subcontracted out. With Nell, we have the products and ip of a technology platform which to be honest I'm not sure what that means as last year it was being kept under wraps as a game changer but no recent mention. Will the new tests sell, maybe? Are the bod convinced they will sell? It appears the retailers are not convinced yet. It looks like we'll be keeping an eye on the amazon best seller list. I really do hope they succeed, they've managed a lot in a short space and have the revenue to make it work.

Initially I did think the new products were selected with retail pharmacies in mind and they might be involved in this process. However it looks like this might only just be happening. Not sure what quite to make of it. There does seem to be whiff of mylotus about it. On the upside the lft revenue will take mhc through for the foreseeable. Pity they didn't previously rns boots supply of the lft as most pretty much guessed they were. GLA

Thought this link to this investment research company's July 15th pdf might be worth posting analysing mercia's portfolio.

https://www.edisongroup.com/publication/excellent-results-despite-the-tough-market/31116/

Quote from page 5:

the publicly traded share price of MyHealthChecked (COVID-19
travel tests, £2.9m write-down) has remained under pressure, although its financial results have been positive.

The signs are for another good update. Hopefully the money markets calculator is fully charged to calculate the fair value for this stock in the coming weeks. GLA

No problem dactions - google is great for this sort of stuff. It's good hear confidence from their largest investor and must bode well for the imminent trading update. We all can see the potential and talent in this business hopefully the market will soon too. GLA

https://m.youtube.com/watch?v=sHVTopZMU4s

About 51mins in useful comments from mercia's latest investor meet presentation with ref to cash/EV and new products. Worth a listen.

jamrock
I like the sound of that:fastest growing company on Aim! The company is certainly at an exciting junction and like most, I'm keen for updates. We have the new app to look forward to which I believe is intended to support the new wellness tests. I'm sure in September they'll provide some sort of fly forward update for even more at home test products. I'm sure they'll adjust the pricing in due course depending on how sales go or who they sell through. The pcr ones were reduced over time I recall. GLA

Interesting to see two private healthcare service providers being quoted in the Sunday Times top 100 uk fastest growing Companies. At positions 3 and 5 respectively we have thriva (2021rev at 74m) and everything genetic (2021rev at 34m). Worth checking out for comparisons. Definitely looks like there is potential in this market and we'll see in a few weeks how mhc is positioning itself.

Nice to have confirmation of a 6 month trading update in July. No mention of the flowflex distribution so I'm intrigued if all the revenue was from the pcr tests or if the lft contributed in any way.

An update on the wellness tests in September seems reasonable. And if no substantive marketing campaign emerges, then hopefully it points to selling the tests through the retailers. Their mylotus test still appears and is available on the boots website so really can't see these not being available through the big pharmacies if mhc want them to be. GLA

Like others have mentioned I thought there might be more of an internet presence for the new tests. I can see from a few searches mhc have targeted a few searches (or maybe it was luck) but no insta/twitter it would seem. Did spot that a new marketing manager started in May 2022 so maybe things are evolving behind the scenes and not yet visible. Previously the MM worked at Wiltshire farm foods with last 2 years responsibile for thier marketing mix. I see the website has 250k visits and in the tough food sector. Hopefully we'll see how mhc plans to market the new tests shortly.

Interesting comments. Just to add a few others I spotted this on the q and a which suggests one method they might use for repeat customers:
Will my results ever change?
Although your DNA never changes we are constantly looking at adding new health areas to our test. As we do not store samples (to meet data protection requirements) you would need to complete a new test to understand your profile in any new health areas

Also, as they report a three level risk approach on a genetic variant and they measure several in a test there might be a greater chance of the customer getting a result that gives them information they find useful. This might nudge them to buy further tests. But granted, this is a newish field, so whether it captures the imagination of the population will be down to the marketing and ensuring it differentiates itself from the single use diagnostic tests.

If we feel mhc are lacking ambition I liked this bit extracted from their website:

Who should take a genetic test?
Anyone and everyone who is interested in knowing themselves on a genetic level. Our tests are designed for beginners looking to improve their lifestyle to elite athletes wanting to improve their performance. Our tests encompass markers for diet, exercise, nutrition and lifestyle risk factors. Yes, bring on the Olympics endorsements! OK this might be a few years away.

The mylotus quantitative lateral flow was fantastic tech but tricky to market in a sensitive market. These tests don't have that barrier so I'm intrigued what their marketing approach will be. Once this happens I'm sure the market will offer their opinion. GLA

I'm pretty impressed with how they've laid out the new tests. It looks like each tests serves between 6 to 10 health areas. I agree with the comments ref exposure. Hopefully they can prise open peoples curiosity about themselves and what these tests can offer over the biomarker tests. If they do that then who wouldn't want to stock them on their website. Certainly interested to see how one this pans out. Well done mhc.

The ceo's comment that the new tests will be supported by positive trading in the COVID space, as over the counter consumer demand continues into 2022 suggests to me otherwise.

Presumably this is from the flowflex distribution rather than pcr tests. Before lloyds upped the flowflex price they were selling in thousands per 24 hrs. Its now in the 100s with the higher price. Boots and superdrug have kept the prices the same but no idea if mhc are the distributors for these two. Hopefully if we have the 6month trading update we can be more certain and hopefully the new tests will be released by then!

Interesting update today. I think it answers a fair few of my questions. The ceo has written 2 sides of A4. It looks to be a bit of a published thank you to the employees of mhc. Given the change in strategy to use third party test facilities and what they managed to achieve in 2021 it makes sense. I guess the employee numbers will halve but hopefully they will find work at ygen. There should be enough testing jobs to go round. Good luck to them.

Initially I thought this change was a backward step but given the glut of post covid testing capacity and the fact they've made a profit using third party test houses then it might be a shrewd move to concentrate on the IP and the face of home testing.

It looks to me to be a retake of 2021 but with our own non covid tests. With the experience they've gained you expect the roll out to follow the same path and timescales. I'm sure they would have talked to the retailers about these tests during the past year - hopefully!

Also interesting comment regarding the distribution of flowflex lateral flow tests. If they are benefitting at the mo then it is likely they are selling beyond their own website and selling through other retailers. We know they use lloyds but wouldn't be surprised if there are a couple of others.

A nimble little enterprise that I'm sure will still surprise!

It looks like the general manager has moved on in the last week according to her comments page:
https://www.linkedin.com/in/jane-kelly-01619216/recent-activity/
It looks like the old cfo has returned to his previous company. People move on all the time but hopefully the next update will help clarify if there is any reason for this. Interesting to read the ceo's summary, as we know very experienced. One line refers to experience of business for sale preparation , any one know if this referred to a pre-mhc role? It probably does but Linkedin is a bit sketchy on this.

Nice one London. Much better sleuthing than the glucose management google image from yesterday. Let's hope this is the start of the turnaround.

If the link doesn't work it shows the glucose management dna swab box. Maybe fits in with the following extracted from an earlier post:The presentation from late last year talked about test panels and the rns from the 24/1/22 references the five tests as:focussing on the areas of weight management, vitamin deficiency, food intolerances, heart health and blood glucose.
Hopefully we'll hear something soon!